Experimental immune therapy combo targets Hard-to-Treat cancers

NCT ID NCT03252938

First seen Jan 23, 2026 · Last updated Apr 28, 2026 · Updated 12 times

Summary

This early-stage trial tests an experimental drug called IMP321, which aims to boost the immune system's ability to fight cancer. It is given alongside standard treatments like chemotherapy or immunotherapy to people with advanced solid tumors that have spread. The main goal is to see if this combination is safe and feasible, with 83 participants receiving the drug through new methods like direct injection into tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Agaplesion Markus Krankenhaus Frankfurter Diakonie Kliniken gGmbH

    Frankfurt, 60431, Germany

  • Helios Dr. Horst Schmidt Klinikum Wiesbaden

    Wiesbaden, 65199, Germany

  • Helios Klinikum Bad Saarow

    Bad Saarow, 15526, Germany

  • Hämatologisch Onkologische Praxis Eppendorf (HOPE)

    Hamburg, 20249, Germany

  • Kliniken der Stadt Köln gGmbH, Studienzentrum der Lungenklinik, Krankenhaus Merheim

    Cologne, 51109, Germany

  • Krankenhaus Nordwest

    Frankfurt, 60488, Germany

  • Marienhospital Herne, Klinik der Ruhr Universität Bochum, Klinik für Urologie

    Herne, 44625, Germany

  • Universität Gießen und Marburg GmbH

    Giessen, 35392, Germany

  • Universitätsklinikum Essen

    Essen, 45147, Germany

  • Universitätsklinikum Tübingen

    Tübingen, 72076, Germany

  • Universitätsklinikum Ulm, Early Clinical Trials Unit (ECTU)

    Ulm, 89081, Germany

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, 55131, Germany

Conditions

Explore the condition pages connected to this study.